Pulse Biosciences shifts focus to cardiac catheter program after AFib study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/1/2026
- Wall St futures slip as US-Iran tensions cloud Middle East peace prospects
- Oil falls as markets await outcome of Iran-US talks, US stocks data
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Dollar firm at 1-year highs as Euro Inflation cools; yen in Intervention zone
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Cantor Fitzgerald Starts Forward Industries (FWDI) at Overweight
- DISH DBS files prepackaged chapter 11 to repay debt, wind down wireless
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Boeing commercial jet deliveries and production disrupted by widespread IT outage - Air Current
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data
March 17, 2026 7:00 AM EDTHAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA), today announced a new strategic alignment to prioritize and accelerate the development and future commercialization of its nPulse Cardiac Catheter Ablation System.
The European feasibility data from over 150 patients sends a definitive message, said Bob Duggan, Co-Chairman of Pulse Biosciences. The nPulse clinical performance demonstrates a clear potential to change clinical practice for the health treatment of millions of patients. Our mission to support this program deserves our highest... More
